Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 2

Поражение нервной системы при болезни Фабри
Е.И. Кимельфельд, Е.А. Кольцова, В.В. Гудкова, Л.В. Стаховская

References

1. Beck M. Fabry disease. Clinical manifestations, diagnosis and therapy. 2nd ed. Oxford, UK: Oxford PharmaGenesis; 2007.
2. Shabber J, Robinson M, Desnick RJ. Detection of α-galactosidase A mutations causing Fabry disease by denaturating high performance liquid chromatography. Human Mutation 2005 Mar;25(3):299-305.
3. Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, Scalia S, Oliveri R, Sciarrino S, Francofonte D, Alessandro R, Pisani A, Palladino G, Napoletano R, Tenuta M, Masarone D, Limongelli G, Riccio E, Frustaci A, Chimenti C, Ferri C, Pieruzzi F, Pieroni M, Spada M, Castana C, Caserta M, Monte I, Rodolico M, Feriozzi S, Battaglia Y, Amico L, Losi M, Autore C, Lombardi M, Zoccali C, Testa A, Postorino M, Mignani R, Zachara E, Giordano A, Colomba P. Mutations in the GLA gene and LysoGb3: is it really Anderson–Fabry disease? International Journal of Molecular Sciences 2018 Dec;19(12):3726.
4. Germain DP. Fabry disease. Orphanet Journal of Rare Disease 2010 Nov;5:30.
5. Barbey F, Hayoz D, Widmer U, Burnier M. Efficacy of enzyme replacement therapy in Fabry disease. Current Medicinal Chemistry. Cardiovascular and Hematological Agents 2004 Oct;2(4):277-86.
6. Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes. Lyso-Gb3 defines Fabry disease. Circulation: Cardiovascular Genetics 2014 Jan;7(1):8-16.
7. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JEM, Poorthuis BJ, Hollak CEM, Aerts JMFG. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochimica et Biophysica Acta 2010 Sep;1802(9):741-8.
8. Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CEM, Poorthuis BJHM. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. Journal of Medical Genetics 2015 Apr;52(4):262-8.
9. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999 Jan;281(3):249-54.
10. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in the Netherlands. Human Genetics 1999 Jul-Aug;105(1-2):151-6.
11. Mehta A, Clarke JTR, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G; FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. Journal of Medical Genetics 2009;46(8):548-52.
12. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA-mutation c.936+919G>A (IVS4+919G>A). Human Mutation 2009 Oct;30(10):1397-405.
13. Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH, Turecek F. Identification of infants at risk for developing Fabry, Pompe, or Mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. The Journal of Pediatrics 2013 Aug;163(2):498-503.
14. Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, Bembi B, Cazzorla C, Rubert L, Zordan R, Desnick RJ, Burlina AP. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in north-east Italy. Journal of Inherited Metabolic Disease 2018 Mar;41(2):209-19.
15. De Brabander I, Yperzeele L, Ceuterick-De Groote C, Brouns R, Baker R, Belachew S, Delbecq J, De Keulenaer G, Dethy S, Eyskens F, Fumal A, Hemelsoet D, Hughes D, Jeangette S, Nuytten D, Redondo P, Sadzot B, Sindic C, Sheorajpanday R, Thijs V, Van Broeckhoven C, De Deyn PP. Phenotypical characterization of @α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clinical Neurology and Neurosurgery 2013 Jul;115(7):1088-93.
16. Mehta A. Fabry disease: a review of current enzyme replacement strategies. Expert Opinion on Orphan Drugs 2015Sep;3(11):1319–30.
17. Maier EM, Osterrieder S, Whybr C, Ries M, Gal A, Beck M, Roscher AA, Munta AC. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatrica. Supplementum 2006 Apr;95(451):30-8.
18. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: management and treatment recommendations for adult patients. Molecular Genetics and Metabolism 2018 Apr;123(4):416-27.
19. Ellaway C. Paediatric Fabry disease. Translational Pediatrics 2016 Jan;5(1):37-42.
20. Laney DA, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, Grange DK, Wilcox WR, Hopkin RJ. Fabry disease in infancy and early childhood: a systematic literature review. Genetics in Medicine 2015 May;17(5):323-30.
21. Kimelfeld EI, Gudkova VV, Gutsalyuk AG, Yushkov AF, Volkova NN, Koltsova EA, Stakhovskaya LV. Repeated ischemic stroke in a young patient with Fabry disease and polysystemic lesion. Consilium Medicum 2017;19(9):12-7 (In Russian).
22. Ries M, Bettis KE, Choyke P, Kopp JB, Austin HA 3rd, Brady RO, Schiffmann R. Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney International 2004 Sep;66(3):978-82.
23. Germain D, Smirnov KA. Fabry’s disease. Nephrology 2012;16(3/1):9-53 (In Russian).
24. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM. Cardiac manifestations of Anderson–Fabry disease: results from the International Fabry Outcome Survey. European Heart Journal 2007 May;28(10):1228-35.
25. Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clinical & Experimental Ophthalmology 2005 Apr;33(2):164-8.
26. Ginsberg L, Valentine A, Mehta A. Fabry disease. Practical Neurology 2005;5:110-3.
27. Lidove O, Chauveheid MP, Caillaud C, Froissart R, Benoist L, Alamowitch S, Doan S, Szalat R, Baumann N, Alexandra JF, Lavallée P, Klein I, Vuillemet F, Sedel F, Sacré K, Samson Y, Roullet E, Papo T. Aseptic meningitis and ischaemic stroke in Fabry disease. The International Journal of Clinical Practice 2009 Nov;63(11):1663-7.
28. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. European Journal of Clinical Investigation 2004 Mar;34(3):236-42.
29. Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small Fiber dysfunction predominates in Fabry neuropathy. Journal of Clinical Neurophysiology 2002 Dec;19(6):575-86.
30. Schiffmann R, Scott LJC. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatrica (Oslo, Norway: 1992) 2002 Jan;91(439):48-52.
31. Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, Møller AT, Hilz MJ. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurology 2011;11:61.
32. Tanislav C, Kaps M, Rolfs A, Böttcher T, Lackner K, Paschke E, Mascher H, Laue M, Blaes F. Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study. European Journal of Neurology 2011 Apr;18(4):631-6.
33. Hoitsma E, Reulen JPH, Baets M, Drent M, Spaans F, Faber CG. Small fiber neuropathy: a common and important clinical disorder. Journal of Neurological Sciences 2004 Dec;227(1):119-30.
34. MacDermot J, MacDermot KD. Neuropathic pain in Anderson–Fabry disease: pathology and therapeutic options. European Journal of Pharmacology 2001 Oct;429(1-3):121-5.
35. Kuzenkova LM, Namazova-Baranova LS, Podkletnova TV, Gevorkyan AK, Vashakmadze ND, Savostyanov KV, Studenikin VM, Pushkov SA. Fabry’s disease: features of disease in children and adolescents. Current Pediatrics 2015;14(3):341-8 (In Russian).
36. Semyachkina AN, Nikolayeva EA, Zakharova EYu, Kharabadze MN. Davydova YuI. Bochenkov SV. Kuramagomedova RG. Fabry disease in children: an analysis of observations and treatment possibilities. Russian Journal of Perinatology and Pediatrics 2018;63(1):71-7 (In Russian).
37. Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: The metabolic and molecular bases of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D, editors. 8th ed. New York, NY: McGraw-Hill; 2001: 3733-74.
38. Biegstraaten M, Linthorst GE, van Schaik IN, Hollak CEM. Fabry disease: a rare cause of neuropathic pain. Current Pain and Headache Reports 2013 Oct;17(10):365.
39. Desnick RJ, Brady RO. Fabry disease in childhood. The Journal of Pediatrics 2004 May;144(5):20-6.
40. Lidove O, Ramaswami U, Jaussaud R, Barbey F, Maisonobe T, Caillaud C, Beck M, Sunder-Plassmann G, Linhart A, Mehta A. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. The International Journal of Clinical Practice 2006 Aug;60:1053-9.
41. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008 Jul;131(Pt 7):1912-25.
42. Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 2000 Feb;84(2-3):361-5.
43. Samuelsson K, Kostulas K, Vrethem M, Rolfs A, Press R. Idiopathic small fiber neuropathy: phenotype, etiologies, and the search for Fabry disease. Journal of Clinical Neurology (Seoul, Korea) 2014 Apr;10(2):108-18.
44. Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, Hutton EJ, Karaa A, Liguori R, Üçeyler N, Zeltzer LK, Burlina A. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neuroscience & Therapeutics 2016 Jul;22(7):568-76.
45. Valeriani M, Mariotti P, Le Pera D, Restuccia D, De Armas L, Maiese T, Vigevano F, Antuzzi D, Zampino G, Ricci R, Tonali P. Functional assessment of A delta and C fibers in patients with Fabry’s disease. Muscle & Nerve 2004 Dec;30(6):708-13.
46. Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP. Belgian Fabry Study. Stroke 2010;41(5):863-8.
47. Schelleckes M, Lenders M, Guske K, Schmitz B, Tanislav C, Ständer S, Metze D, Katona I, Weis J, Brand SM, Duning T, Brand E. Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A-10T genotype. Orphanet Journal of Rare Diseases 2014 Nov;9:178.
48. Germain DP, Avan P, Chassaing A, Bonfils P. Erratum to: Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Medical Genetics 2004;23;5(1).
49. Köping M, Shehata-Dieler W, Schneider D, Cebulla M, Oder D, Müntze J, Nordbeck P, Wanner C, Hagen R, Schraven SP. Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet Journal of Rare Diseases 2018 Aug;13(1):137.
50. Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Rare Kidney Diseases. Contributions to Nephrology 2001 Feb;136(136):234-40.
51. Conti G, Sergi B. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatrica (Oslo, Norway: 1992). Supplement 2003 Dec;92(443):33-7; discussion 27.
52. Burlina A, Politei J. The central nervous system involvement in Fabry disease: a review. Journal of Inborn Errors of Metabolism and Screening 2016 Jan;4:e160039.
53. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke 2009 Mar;40(3):788-94.
54. Nakamura K, Sekijima Y, Nakamura K, Hattori K, Nagamatsu K, Shimizu Y, Yasude T, Ushiyama M, Endo F, Fukushima Y, Ikeda S. Cerebral hemorrhage in Fabry’s disease. Journal of Human Genetics 2010 Apr;55(4):259-61.
55. Reisin RC, Romero C, Marchesoni C, Nápoli G, Kisinovsky I, Cáceres G, Sevlever G. Brain MRI findings in patients with Fabry disease. Journal of the Neurological Sciences 2011 Jun;305(1-2):41-4.
56. Rombach SM, van den Bogaard B, de Groot E, Groener JEM, Poorthuis BJ, Linthorst GE, van den Born BJH, Hollak CEM, Aerts JMFG. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012 Oct;60(4):998-1005.
57. Aerts JM, Groener JE, Kulper S. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proceedings of the National Academy of Sciences of the USA 2008 Feb;105(8):2812-7.
58. Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. European Heart Journal 2010 Jan;31(1):67-76.
59. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. Journal of Neurology 2004 May;251(5):564-70.
60. Rombach SM, Twickler TB, Aerts JMFG, Linthorst GE, Wijburg FA, Hollak CEM. Vasculopathy in patients with Fabry disease: current controversies and research directions. Molecular Genetics and Metabolism 2010 Feb;99(2):99-108.
61. Vedder AC, Linthorst GE, van Breemen MJ, Groener JEM, Bemelman FJ, Strijland A, Mannens MMAM, Aerts JMFG, Hollak CEM. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. Journal of Inherited Metabolic Disease 2007 Feb;30(1):68-78.
62. Mehta A, Ginsberg L. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatrica (Oslo, Norway: 1992) 2007 Jan;94:24-7.
63. Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, Politei J, Manara R, Burlina A. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 2015;46(1):302-13.
64. Marchesoni C, Romero C, Sevlever G, Pardal A, Kisinovsky I, Quarin A, Cáceres G, Reisin R. Brain MRI findings in Fabry disease. Journal of the Neurological Sciences 2013 Oct;333(Suppl 1):e179-80.
65. Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, Mignani R, Parini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W. Central nervous system involvement in Anderson–Fabry disease: a clinical and MRI retrospective study. Journal of Neurology, Neurosurgery & Psychiatry 2008 Nov;79(11):1249-54.
66. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. Journal of the Neurological Sciences 2007 Mar;257(1-2):258-63.
67. Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, Böttcher T, Heuschmann PU, Tatlisumak T, Tanislav C, Jungehulsing GJ, Giese AK, Putaala J, Huber R, Bodechtel U, Lichy C, Enzinger C, Schmidt R, Hennerici MG, Kaps M, Kessler C, Lackner K, Paschke E, Meyer W, Mascher H, Riess O, Kolodny E, Norrving B. Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke 2013 Feb;44(2):340-9.
68. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, Desnick RJ. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010 Jan;41(1):78-81.
69. Baptista MV, Ferreira S, Pinho-e-Melo T, Carvalho M, Cruz VT, Carmona C, Silva FA, Tuna A, Rodrigues M, Ferreira C, Pinto AAN, Leitão A, Gabriel JP, Calado S, Oliveira JP, Ferro JM; PORTuguese Young STROKE Investigators. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study – screening genetic conditions in Portuguese young stroke patients. Stroke 2010 Mar;41(3):431-6.
70. Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. The Lancet 2005 Nov;366(9499):1794-6.
71. Linthorst GE, Ginsberg L. Prevalence of Fabry disease in TIA/stroke cohorts. What defines Fabry disease? European Journal of Neurology 2012 Nov;19(11):1383-4.
72. Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry’s disease. The Lancet. Neurology 2006 Sep;5(9):791-5.
73. Lin YJ, Huang YT, Po HL. Hypertensive encephalopathy and multiple ischemic stroke as initial presentation of Fabry disease. In: The 4th European Stroke Organisation Conference, 2018: abstracts. European Stroke Journal 2018 May;3(1 Suppl):427. AS19-058.
74. Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, Böttcher T, Fazekas F, Rolfs A. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovascular Diseases (Bazel, Switzerland) 2011;31(3):294-9.
75. Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina A, Lidove O. The pulvinar sign: frequency and clinical correlations in Fabry disease. Journal of Neurology 2008 May;255(5):738-44.
76. Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR. American Journal of Neuroradiology 2003 Jun-Jul;24(6):1096-101.
77. Burlina AP, Politei J, Cinque S, Soliani A, Carlier RY, Germain DP, Manara R. The pulvinar sign in Fabry patients: the first report in female patients. Journal of Neurology 2012 Jun;259(6):1227-8.
78. Castaneda JA, Lim MJ, Cooper JD, Pearce DA. Immune system irregularities in lysosomal storage disorders. Acta Neuropathologica 2008 Feb;115(2):159-74.
79. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Molecular Genetics and Metabolism 2017 Feb;122(3):19-27.
80. Yanagimura F, Fukushima T, Sakamaki Y, Nakamura G, Maruyama H, Makino K. Fabry disease associated with chronic meningitis and cerebral infarction. Neurology and Clinical Neuroscience 2015 Jul;3(4):147-9.
81. Schreiber W, Udvardi A, Kristoferitsch W. Chronic meningitis and lacunar stroke in Fabry disease. Journal of Neurology 2007 Oct;254(10):1447-9.
82. Uyama E, Ueno N, Uchino M, Narahara T, Owada M, Taketomi T, Ando M. Headache associated with aseptic meningeal reaction as clinical onset of Fabry’s disease. Headache 1995 Sep;35(8):498-501.
83. Böttcher T, Rolfs A, Tanislav C, Bitsch A, Köhler W, Gaedeke J, Giese AK, Kolodny EH, Duning T. Fabry disease – underestimated in the differential diagnosis of multiple sclerosis? PLoS One 2013 Aug;8(8):e71894.
84. Colomba P, Zizzo C, Alessandro R, Cammarata G, Scalia S, Giordano A, Pieroni M, Sicurella L, Amico L, Burlina A, Duro G. Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs. Oncotarget 2018 Jan;9(8):7758-62.
85. Curiati MA, Aranda CS, Kyosen SO, Varela P, Pereira VG, D’Almeida V, Pesquero JB, Martins AM. The challenge of diagnosis and indication for treatment in Fabry disease. Journal of Inborn Errors of Metabolism and Screening 2017 Jan;5:1-7
86. Fervenza FC, Torra R, Warnock DG. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics: Targets & Therapy 2008 Dec;2(4):823-43.
87. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001 Jun;285(21):2743-9.
88. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ; Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of Internal Medicine 2007 Jan;146(2):77-86.
89. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008 Feb;94(2):153-8.
90. Mehta A, Beck M, Kampmann C, Frustaci A, Germain DP, Pastores GM, Sunder-Plassmann G. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Molecular Genetics and Metabolism 2008 Sep-Oct;95(1-2):114-5.
91. Tsuboi K, Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genetics in Medicine 2012 Sep;14(9):779-86.
92. Vedder AC. Treatment of Fabry patients greater than 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0.2 mg/kg) Fabrazyme® (agalsidase beta) or Replagal® (agalsidase alfa). Available from: http://www.isrctn.com/ISRCTN45178534 Accessed 2020 Jun 30.
93. Ministry of Health of the Russian Federation. Federal clinical guidelines for diagnosis and treatment of Fabry disease. Draft 19.01.13. Moscow, 2013. 26 p. (In Russian).
94. Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst G.E, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. Journal of Medical Genetics 2015 May;52(5):353-8.
95. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle & Nerve 2003 Dec;28(6):703-10.
96. Hajioff D, Hegemann S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, Mehta A, Keilmann A. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. European Journal of Clinical Investigation 2006 Sep;36(9):663-7.
97. Jardim LB, Gomes I, Netto CBO, Nora DB, Matte US, Pereira F, Burin MG, Kalakun L, Giugliani R, Becker J. Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease. Journal of Inherited Metabolic Disease 2006 Oct;29(5):653-9.
98. Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). Journal of Medical Genetics 2005;42(3):247-52.
99. Sheng S, Wu L, Nalleballe K, Sharma R, Brown A, Ranabothu S, Kapoor N, Onteddu S. Fabry’s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. Journal of Clinical Neuroscience 2019 Jul;65:83-6.
100. Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, Hense HW, Beck M, Brand SM, Brand E. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology 2015 Mar;84(10):1009-16.
101. Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovascular Diseases (Basel, Switzerland) 2014;38(6):448-56.
102. European Medicines Agency. Migalastat (galafold): EU summary of product characteristics. 2018. Available from: https://www.ema.europa.eu/ Accessed 2020 Jul 09.
103. Amicus Therapeutics. Galafold™ (migalastat) capsules, for oral use: US prescribing information. 2018. Available from: https://www.fda.gov/. Accessed 2020 Jul 09.
104. Health Canada. Galafold™ (migalastat) capsules: Canadian product monograph 2017. Available from: https://pdf.hres.ca/dpd_pm/00041104.PDF Accessed 2020 Jul 09.
105. Eng CM, Germain DP, Banikazemi M. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genetics in Medicine 2006 Sep;8(9):539-48.
106. Hughes DA, Mehta AB. Vascular complications of Fabry disease: enzyme replacement and other therapies. Acta Paediatrica (Oslo, Norway: 1992) Supplement 2005 Mar;94(447):28-33; discussion 9-10.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]